-ster-
Male sex hormones and muscle-building steroids.
- Drugs inside -ster-: 25
- Approved somewhere: 12
- With a US drug page: 15
- Stem
- -ster-
- Class
- Male sex hormones and muscle-building steroids
- Sub-stems
- -steride
Approved and clinical-stage drugs in ChEMBL whose names inside -ster- or one of its sub-stems, matched by spelling; those with a US drug page link to it.
| Acts on | |||
|---|---|---|---|
| Fluoxymesterone | Approved | AR | Androgen Receptor agonist |
| Hydroxyprogesterone caproate | Approved | PGR | Progesterone receptor agonist |
| Medroxyprogesterone acetate | Approved | PGR | Progesterone receptor agonist |
| Methyltestosterone | Approved | AR | Androgen Receptor agonist |
| Prasterone | Approved | — | Unknown |
| Progesterone | Approved | PGR | Progesterone receptor agonist |
| Testosterone | Approved | AR | Androgen Receptor agonist |
| Testosterone cypionate | Approved | AR | Androgen Receptor agonist |
| Testosterone enanthate | Approved | AR | Androgen Receptor agonist |
| Testosterone undecanoate | Approved | AR | Androgen Receptor agonist |
| Dydrogesterone | Phase 3 | PGR | Progesterone receptor agonist |
| Desoxycorticosterone acetate | — | NR3C2 | Mineralocorticoid receptor agonist |
| Desoxycorticosterone pivalate | — | NR3C2 | Mineralocorticoid receptor agonist |
| Bezisterim | Phase 3 | — | — |
| Corticosterone | Phase 3 | — | — |
| Ethisterone | Phase 3 | — | — |
| Fluorofuranylnorprogesterone | Phase 2 | — | — |
| Larsucosterol | Phase 2 | — | — |
| Rivasterat | Phase 2 | — | — |
| Cholesterol | Phase 1 | — | — |
| Testosterone propionate | Phase 1 | AR | Androgen Receptor agonist |
| Dihydrotachysterol | — | VDR | Vitamin D receptor agonist |
| Segesterone acetate | — | PGR | Progesterone receptor agonist |
| Dutasteride | Approved | Steroid 5-alpha-reductase | Steroid 5-alpha-reductase inhibitor |
| Finasteride | Approved | SRD5A2 | Steroid 5-alpha-reductase 2 inhibitor |
Stem from WHO, The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances (2024); description written by Arca. Drugs, stages, targets and mechanisms from ChEMBL (CC BY-SA 3.0). WHO